Press-release for stocks

Prices are updated after-hours

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma
Published: 2022-12-21 (Crawled : 22:00) - investors.phiopharma.com
PHIO | $0.63 -2.93% -3.02% 62K

| -85.56% | O: 9.33% H: 0.0% C: -12.49%
ph-762 treatment pharmaceuticals program study cell carcinoma

| -70.85% | O: 11.66% H: 10.44% C: -3.21%
positive cancer treatment

64%

36%

AGBA | News | $1.02 155.0% 57.94% 120M

ZCMD | $2.86 108.76% 52.1% 2.3M

INVO | $1.555 104.6% 51.13% 5M

ISPC | $0.437 105.16% 49.53% 37M

WLGS | News | $0.92 84.0% 45.65% 1.6M

OST | $0.499 21.38% 45.26% 1.9M

XPON | News | $3.1 60.62% 37.74% 17M

TIRX | $0.7 44.39% 30.74% 58M

BNTC | News | $6.92 44.17% 30.64% 3.5M

GGE | $0.035 19.86% 29.3% 64M

Save your searches and get alerts when important news are released.